TCGX Raised $600 Million for Asian Biotech Fund
The firm expanded into Shanghai and Hong Kong to capture growing biotech innovation across Asia.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Is now a good time for firms to increase investment in international biotechnology research?
TCGX has raised $600 million for its new Asia Life Sciences Fund I, marking a strategic expansion into the region. The firm has also opened offices in Shanghai and Hong Kong to source and support biotech companies.
Why it matters
The firm identified Asia as an increasingly important source of globally competitive biotechnology innovation. This fund aims to apply the firm's existing Western investment playbook to the Asian market in synergy with its broader portfolio.
The new $600 million fund brings TCGX's total capital under management to $3.1 billion. This follows a string of significant biotech exits and fundings, including the $2.7 billion purchase of Carmot Therapeutics and a $446 million IPO for ADARx Pharmaceuticals in September 2026.
The players
TCGX
A California-based investment firm with $3.1 billion in total capital that focuses on funding biotechnology companies.
Dandan Dong
The managing partner of TCGX in Asia who joined the firm in 2024 to lead its regional expansion.
The details
TCGX is deploying an investment model used in its Western vehicles to target emerging biotech opportunities in the Asian market. The firm manages these efforts through its new local presence in Shanghai and Hong Kong under managing partner Dandan Dong. The strategy operates in synergy with existing vehicles while specifically targeting companies with globally competitive innovation profiles.
Timeline
2021: TCGX raised its first $824 million fund.
Late 2023: Roche and Bristol Myers Squibb acquired portfolio companies.
2024: Dandan Dong joined TCGX.
2025: Novartis acquired Tourmaline Bio.
September 2026: ADARx Pharmaceuticals completed an IPO.
The Tech Race
This expansion places TCGX directly into the competitive race for Asian biotech innovation, following a period of high-value industry activity including the $4.1 billion acquisition of RayzeBio by Bristol Myers Squibb. The fund aims to replicate the success of Western-led investment cycles in a market that has increasingly produced major pharmaceutical exit events.
The firm's new capital will likely accelerate the development timelines for early-stage biotechnology companies across Asia by providing access to broader global networks and funding resources. Researchers and startups in the region may see increased opportunities for partnerships that bridge Asian innovation with Western clinical and commercial markets.
The takeaway
TCGX is betting that the pipeline of Asian biotechnology innovation is ready for increased global integration. Investors and industry analysts should monitor the firm's future portfolio announcements to see which therapeutic areas are prioritized under the new fund.
Further reading
For more on the investment landscape, visit the Biotech section.
Live Poll
Is now a good time for firms to increase investment in international biotechnology research?
